Roivant Sciences

Zest Health, LLC is a Chicago-based company that develops a mobile application designed to enhance healthcare navigation for consumers, employers, and providers. The application features several tools, including "Talk to Me," which provides immediate phone access to medical experts; "Schedule Me," for booking medical appointments; "Inform Me," which offers health-related information similar to WebMD; and "Track Me," which allows users to store their electronic health records. Zest Health's solution focuses on strategic buying, access to healthcare professionals, and preventative care and disease management programs. As a subsidiary of Roivant, Zest also operates Zest Dermatology, a virtual clinic that specializes in high-quality, cost-effective care for patients with conditions like eczema and psoriasis. By partnering with health plans, employers, and dermatologists, Zest aims to optimize dermatology care and reduce specialty drug costs, while participating in initiatives to improve patient outcomes.

Immunovant, headquartered in New York, is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with autoimmune diseases. Its primary focus is on developing monoclonal antibodies, notably IMVT-1401, a fully human antibody that targets the neonatal Fc receptor (FcRn). This investigational product is designed for subcutaneous injection and aims to address various IgG-mediated autoimmune conditions. IMVT-1401 is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials also initiated for warm autoimmune hemolytic anemia. Additionally, the company is developing batoclimab and IMVT-1402, both targeting FcRn.

Lokavant is an information technology company that specializes in providing clinical trial intelligence. It offers real-time monitoring and anticipatory analytics aimed at enhancing the management of clinical trials. By utilizing advanced analytics and visualization techniques, Lokavant enables rigorous analysis and proactive risk management, simplifying the monitoring process for clinical trials. The company's services include real-time visualizations, risk alerts, and a combination of artificial intelligence and human insights, all designed to improve the efficiency and effectiveness of clinical research.

Medallion is a company that offers a network management platform tailored for the healthcare industry, focusing on simplifying the complex processes of licensing, credentialing, and payer enrollment. Founded in 2020 by Derek Lo and based in San Francisco, California, Medallion's all-in-one platform addresses the logistical challenges that healthcare providers and telemedicine companies face, enabling them to minimize time spent on administrative tasks. Key features of the platform include facilities for new licensing and renewals, primary source verification, continuing medical education tracking, and document management. By streamlining these processes, Medallion allows healthcare professionals to concentrate more on patient care rather than paperwork.

Gen-t is a Brazilian company founded in 2021, based in Sao Paulo, that focuses on genomic research through a diverse genetic biobank. The platform emphasizes the ethnic diversity of Brazil, providing researchers with access to genetic data that reflects the country's unique population admixture. This rich genetic resource aims to foster innovation across various fields, particularly in biotechnology, by enabling the development of more effective medicines and treatments tailored to the specific health needs of the Brazilian populace. Gen-t's efforts contribute to advancing the understanding of genetics and its applications in addressing diseases prevalent within the diverse Brazilian demographic.

Immunovant, headquartered in New York, is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with autoimmune diseases. Its primary focus is on developing monoclonal antibodies, notably IMVT-1401, a fully human antibody that targets the neonatal Fc receptor (FcRn). This investigational product is designed for subcutaneous injection and aims to address various IgG-mediated autoimmune conditions. IMVT-1401 is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials also initiated for warm autoimmune hemolytic anemia. Additionally, the company is developing batoclimab and IMVT-1402, both targeting FcRn.

Silicon Therapeutics is a drug design and development company that specializes in computational drug discovery. The company employs a physics-driven approach to drug design, integrating chemistry and biology research to create novel small molecule therapeutics. Its unique platform is designed to target challenging protein targets that are biologically and genetically validated but have historically been difficult to address. By simulating interactions and conformational behaviors of biological molecules using the laws of physics, Silicon Therapeutics enhances the understanding of the relationship between protein conformations and biological outcomes, ultimately advancing the field of biotechnology and expanding the possibilities in drug discovery.

Datavant, Inc. is a health data platform company based in San Francisco, California, founded in 2017. The company specializes in aggregating and analyzing biomedical data using machine learning to enhance the efficiency of drug development. It focuses on improving the clinical trial process by employing artificial intelligence and organizing healthcare data to derive actionable insights for trial design and interpretation. By facilitating secure and accessible data connectivity, Datavant enables over 60 million healthcare records to be exchanged among thousands of organizations, including more than 70,000 hospitals and clinics. The company serves the clinical development and commercial pharmaceutical sectors, as well as researchers, and aims to improve patient outcomes while protecting patient privacy through its innovative platform.

Patara Pharma, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapeutics for allergic and inflammatory diseases affecting specific patient populations. The company's lead product, PA101B, is a GPR35 agonist that functions as an immune modulator with mast cell stabilizing properties. This therapy is aimed at treating chronic cough that is resistant to existing treatments, particularly in individuals with idiopathic pulmonary fibrosis, as well as patients diagnosed with indolent systemic mastocytosis, a rare condition. Founded in 2013, Patara Pharma seeks to address unmet medical needs in orphan and specialized patient groups through innovative therapies.

Datavant, Inc. is a health data platform company based in San Francisco, California, founded in 2017. The company specializes in aggregating and analyzing biomedical data using machine learning to enhance the efficiency of drug development. It focuses on improving the clinical trial process by employing artificial intelligence and organizing healthcare data to derive actionable insights for trial design and interpretation. By facilitating secure and accessible data connectivity, Datavant enables over 60 million healthcare records to be exchanged among thousands of organizations, including more than 70,000 hospitals and clinics. The company serves the clinical development and commercial pharmaceutical sectors, as well as researchers, and aims to improve patient outcomes while protecting patient privacy through its innovative platform.

Arbutus Biopharma Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for chronic hepatitis B virus (HBV) infection. The company has a comprehensive pipeline that includes AB-836, a capsid inhibitor designed to prevent HBV replication, and AB-423, currently in pre-clinical studies. Arbutus is also developing RNA interference (RNAi) therapeutics aimed at reducing hepatitis B surface antigen levels in infected patients. Notable candidates include AB-729, a second-generation RNAi therapeutic targeting liver cells, and an orally active HBV RNA destabilizer to promote RNA degradation. Additionally, Arbutus is conducting clinical trials and pre-clinical studies to evaluate its proprietary HBV therapies in combination with standard care treatments. The company engages in strategic alliances and collaborations to enhance its research and development efforts. Headquartered in Warminster, Pennsylvania, Arbutus Biopharma was formerly known as Tekmira Pharmaceuticals Corporation before rebranding in July 2015.